XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Operating activities    
Net loss $ (11,223) $ (10,993)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 90 31
Stock-based compensation expense 1,064 1,152
Amortization of premiums (discounts) on short-term investments (163) 346
Release of clinical trial funding commitment 0 139
Changes in operating assets and liabilities:    
Other assets 26 51
Accounts receivable and unbilled receivable 95 88
Prepaid expenses and other assets 1,251 (1,141)
Operating lease right-of-use assets 136 136
Accounts payable and accrued expenses 203 0
Operating lease liabilities (138) (16)
Other liabilities 0 (42)
Net cash used in operating activities (8,659) (10,249)
Investing activities:    
Capital expenditures (8) (171)
Maturities of short-term investments 42,983 38,217
Purchases of short-term investments (37,327) (36,773)
Sales of short-term investments 1,681 17,085
Net cash provided by investing activities 7,329 18,358
Financing activities:    
Net cash provided by financing activities 0 0
Net change in cash and cash equivalents (1,330) 8,109
Cash and cash equivalents—Beginning of period 16,347 11,943
Cash and cash equivalents—End of period 15,017 20,052
Supplementary disclosure of cash flow activity:    
Cash paid for taxes 0 1
Supplemental disclosure of non-cash investing and financing activities:    
Acquisition of property and equipment included in accounts payable and accrued expenses $ 133 $ 27